Adagio Medical Holdings, Inc. (Nasdaq: ADGM), a leader in catheter ablation technologies for treating cardiac arrhythmias, announced today that founder Olav Bergheim has stepped down as Chief Executive Officer (CEO) and Chairperson of the Board of Directors, effective December 13, 2024. The company also revealed the appointment of Todd Usen as CEO and Director, and Orly Mishan as Chairperson of the Board, effective the same day. Mr. Bergheim will continue to support the company as an advisor and assist Mr. Usen with the transition until December 13, 2025.
Orly Mishan, Chairperson of the Board, expressed gratitude for Bergheim’s leadership, acknowledging his pivotal role in advancing Adagio. “We are grateful to Olav for his dedication and contributions to Adagio. Under his leadership, the company made substantial clinical and operational strides and achieved the milestone of being NASDAQ-listed,” Mishan said.
Todd Usen, the new CEO, brings a wealth of experience to Adagio. His background includes leading large and complex medical device companies and driving both corporate development and product innovation. Usen has a proven track record of successfully restructuring and growing organizations, and his expertise spans operational logistics, go-to-market strategies, and fundraising. Before joining Adagio, Usen was President & CEO of Minerva Surgical, where he restructured the organization and successfully increased top-line growth. He has also held leadership roles at Activ Surgical, Olympus Corporation, Smith & Nephew, and Boston Scientific.
“I’m thrilled to join Adagio at this important junction in the company’s history, supporting initial commercial efforts in Europe and the FULCRUM-VT trial enrollment in the United States,” Usen said. “With growing evidence demonstrating both the safety and effectiveness of Adagio’s Ultra-Low Temperature Cryoablation technology, I believe that Adagio’s VT Cryoablation System with vCLAS™ catheter will become the future standard of care for treating patients with ventricular tachycardia.”
Bergheim, reflecting on his tenure at Adagio, remarked, “It has been an honor to lead Adagio over the last 13 years, delivering on our mission of improving the quality of life and long-term outcomes for patients with cardiac arrhythmias. I am proud of what we have accomplished together, and I am confident that Adagio is poised for continued success.”
Adagio Medical Holdings is focused on developing innovative cryoablation technologies that create contiguous, transmural lesions to treat various cardiac arrhythmias. The company’s products are used for treating conditions such as paroxysmal and persistent atrial fibrillation, atrial flutter, and ventricular tachycardia. The company is currently engaged in the FULCRUM-VT trial, which is investigating the use of Adagio’s Ultra-Low Temperature Cryoablation technology for drug-refractory ventricular tachycardia (VT).
The FULCRUM-VT study (Feasibility of Ultra-Low Temperature Cryoablation in Recurring Monomorphic Ventricular Tachycardia) is a prospective, multi-center, open-label study enrolling 206 patients with structural heart disease. This trial will evaluate the safety and efficacy of Adagio’s VT Cryoablation System, which features the vCLAS™ cryoablation catheter. The data gathered from this study will be used to seek FDA premarket approval for the system, which would offer the broadest indication for endocardial ablation of scar-mediated VT.
With Usen at the helm, Adagio Medical is poised for continued growth and innovation in the cardiac ablation space, with a clear focus on improving patient outcomes through cutting-edge technology.
